Combination Therapy Testing Service

Online Inquiry

The Necessary of Combination Therapy Development

Tumor-infiltrating lymphocyte (TIL) therapy is a promising immunotherapy approach that involves harvesting a patient's tumor-infiltrating T cells, expanding them ex vivo, and reinfusing them to enhance their anti-tumor activity. While TIL therapy has demonstrated significant efficacy in treating metastatic melanoma, its application to solid tumors remains challenging due to the immunosuppressive tumor microenvironment. Further research is necessary to optimize TIL therapy and overcome these limitations, thereby expanding its potential to treat a wider range of solid tumors.

Combination Therapy Testing Service at Creative Biolabs

Combining immunotherapy with other cancer treatments offers a synergistic approach to enhance efficacy and overcome the limitations of single-agent therapies. Creative Biolabs offers comprehensive combination TIL therapy testing services to accelerate the development of innovative cancer treatments. Our experienced team specializes in isolating and expanding TILs from patient tumors, designing custom combination therapies, and conducting rigorous in vitro and in vivo testing. Leveraging advanced data analytics, we identify the most effective and well-tolerated treatment combinations. Our personalized approach guarantees that each customer's requirements are satisfied, enabling prompt and effective results delivery.

Fig.1 The combination of TIL therapy and other therapies. Fig.1 Combining TIL treatment with other therapies.¹

Popular Combination TIL Therapy Strategies

Here we provide several common strategies for references:

TIL Therapy Combined with Checkpoint Inhibitors

Rationale: By inhibiting immune checkpoints that cancer cells exploit to evade immune surveillance, checkpoint inhibitors such as PD-1/PD-L1 inhibitors can potentiate the efficacy of TIL therapy, leading to a more robust anti-tumor response.

Synergy: TIL therapy can activate the immune system, while checkpoint inhibitors can prevent the tumor from suppressing this response.

TIL Therapy Combined with Chemotherapy

Rationale: Chemotherapy can reduce the tumor burden and create a more favorable environment for TIL therapy.

Synergy: Chemotherapy can induce tumor cell death, releasing tumor antigens that can further stimulate the TILs.

TIL Therapy Combined with Radiation Therapy

Rationale: Radiation therapy can damage tumor cells and release tumor-associated antigens.

Synergy: The combination can enhance the immunogenicity of the tumor and promote a more robust T cell response.

TIL Therapy Combined with Adoptive Cell Therapy (ACT)

Rationale: Combining TIL therapy with other ACTs, such as CAR-T cell therapy, can provide a broader and more potent anti-tumor response.

Synergy: Different T cell populations can target different tumor antigens and work together to eliminate the cancer.

Key In Vitro Assays for Combination TIL Therapy

In vitro testing provides a valuable foundation for selecting promising combination therapies that can be further evaluated in preclinical animal models and ultimately in clinical trials. Our in vitro testing covers a full range of tests from performance to function, including:

Cytotoxicity Assays
Proliferation Assays
Cytokine and Chemokine Production Assays
Phenotypic Analysis
Functional Assays

Commonly Used Animal Models for In Vivo Testing

Simulating human cancers in real animal models allows us to gain a better understanding of the interaction between combination therapy and tumor cells, other therapeutic medications, and the overall impact on the body. Commonly used animal models include:

Immunodeficient mouse model: Commonly used to study the growth and metastasis of tumor cells, as well as the anti-tumor activity of TILs.
Humanized mouse model: By transplanting human tumor cells or tissues, it can better simulate the human tumor microenvironment and evaluate the clinical translation potential of TIL therapy.
Genetically engineered mouse model: A mouse model with specific gene mutations or knockouts can be constructed to study the role of specific molecular targets

Work with Creative Biolabs

Fig.2 Partner. (Creative Biolabs Original)

As a leading innovator in immunotherapy, Creative Biolabs is dedicated to advancing TIL therapy. Our team of experts is constantly exploring novel strategies to overcome the limitations of traditional TIL therapy. By offering comprehensive combination therapy testing services, we strive to accelerate the development of innovative cancer treatments. Contact us today to learn more about your specific needs and explore how our expertise can help you.

Reference

Zhao, Yueshui, et al. "Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges." Cancers 14.17 (2022): 4160. Distributed under Open Access license CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.